|
|
|
|
Auxilium Pharmaceuticals, Inc.: U.S. Food and Drug Administration's Arthritis Advisory Committee Sets Tentativ
Food and Drug Administration's Arthritis Advisory Committee Sets Tentative Date to Review XIAFLEXTM for the Treatment of Dupuytren's Contracture MALVERN, PA--(Marketwire - June 18, 2009) - Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL...
|
|
|
U.S. Food and Drug Administration's Arthritis Advisory Committee Sets Tentative Date to Review XIAFLEX(TM) for
Food and Drug Administration's Arthritis Advisory Committee Sets Tentative Date to Review XIAFLEX(TM) for the Treatment of Dupuytren's Contracture More News related to AUXL More News related to Press Releases MALVERN, PA -- (MARKET...
|
|
|
U.S. Food and Drug Administration's Arthritis Advisory Committee Sets Tentative Date to Review XIAFLEX(TM) for
Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee will review XIAFLEX(TM) during an advisory committee...
|
|
|
U.S. Food and Drug Administration's Arthritis Advisory Committee Sets Tentative Date to Review XIAFLEX(TM) for
MALVERN, PA -- (Marketwire) -- 06/18/09 -- Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee will review...
|
|
|
U.S. Food and Drug Administration's Arthritis Advisory Committee Sets Tentative Date to Review XIAFLEX(TM) for
More News related to AUXL More News related to Press Releases MALVERN, PA -- (MARKET WIRE) -- 06/18/09 -- Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug...
|
|
|
U.S. Food and Drug Administration's Arthritis Advisory Committee
Auxilium Pharmaceuticals, Inc.(NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee will review XIAFLEX(TM) during an advisory committee...
|
|
|
U.S. Food and Drug Administration's Arthritis Advisory Committee Sets Tentative Date to Review XIAFLEX(TM) for
XIAFLEX (collagenase clostridium histolyticum) is a novel, first-in-class, orphan-designated, biologic for the treatment of Dupuytren's contracture.Auxilium filed its Biologics License Application (BLA) for XIAFLEX for the treatment of...
|
|
|
U.S. Food and Drug Administration's Arthritis Advisory Committee Sets Tentative Date to Review XIAFLEX(TM) for
- Auxilium Pharmaceuticals, Inc.(NASDAQ XIAFLEX (collagenase clostridium histolyticum) is a novel, first-in-class, orphan-designated, biologic for the treatment of Dupuytren's contracture. Auxilium filed its Biologics License...
|
|
|
Corrective Osteotomies and Osteosynthesis for Supination Contracture of the Forearm in Children
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Journal of Pediatric Orthopaedics , 06/12/09 Print Save in My Library Free Abstract Rolfe KW et al.- Distal ulnar and midradial osteotomies are effective...
|
